Agendia BV Release: Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
6/3/2013 10:28:28 AM
More...
|
Agendia BV Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
1/25/2013 9:14:06 AM
More...
|
Agendia BV Announces Discovery of a Gene Signature That Predicts Response to a Broad Range of Cancer Drugs
11/27/2012 9:47:35 AM
More...
|
Agendia BV Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
9/14/2012 11:50:18 AM
More...
|
Agendia BV Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
8/31/2012 8:25:08 AM
More...
|
Agendia BV Earns ISO Certification for Facilities in Amsterdam and Irvine
8/21/2012 10:47:04 AM
More...
|
Agendia BV Appoints Dr. Stefan Gluck to Chair Medical Advisory Board
8/9/2012 10:28:33 AM
More...
|
Agendia BV Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
7/10/2012 11:14:04 AM
More...
|
Agendia BV Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
7/9/2012 10:40:57 AM
More...
|
Agendia BV Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
6/1/2012 10:40:03 AM
More...
|
|